143 related articles for article (PubMed ID: 35865820)
1.
Jiang H; Xiong J; Tan L; Jin P; Sun Y; Yang L; Tan J
Front Cell Infect Microbiol; 2022; 12():936814. PubMed ID: 35865820
[TBL] [Abstract][Full Text] [Related]
2. Interactions between antifungals and everolimus against
Liang P; Song J; Liu Q
Front Cell Infect Microbiol; 2023; 13():1131641. PubMed ID: 37026056
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the synergistic antifungal activity of everolimus and antifungal drugs against dematiaceous fungi.
An L; Jia G; Tan J; Yang L; Wang Y; Li L
Front Cell Infect Microbiol; 2023; 13():1131416. PubMed ID: 36909734
[TBL] [Abstract][Full Text] [Related]
4.
Jia G; Hu J; Tan L; Li L; Gao L; Sun Y
Microbiol Spectr; 2023 Jun; 11(3):e0530222. PubMed ID: 37140396
[TBL] [Abstract][Full Text] [Related]
5.
Sun Y; Tan L; Yao Z; Gao L; Yang J; Zeng T
Microbiol Spectr; 2022 Feb; 10(1):e0200721. PubMed ID: 35019705
[TBL] [Abstract][Full Text] [Related]
6. In Vitro Interactions between Target of Rapamycin Kinase Inhibitor and Antifungal Agents against Aspergillus Species.
Gao L; Ding X; Liu Z; Wu Q; Zeng T; Sun Y
Antimicrob Agents Chemother; 2016 Jun; 60(6):3813-6. PubMed ID: 26976874
[TBL] [Abstract][Full Text] [Related]
7. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.
Pfaller MA; Messer SA; Hollis RJ; Jones RN;
Antimicrob Agents Chemother; 2002 Apr; 46(4):1032-7. PubMed ID: 11897586
[TBL] [Abstract][Full Text] [Related]
8. Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
Lass-Flörl C; Mayr A; Perkhofer S; Hinterberger G; Hausdorfer J; Speth C; Fille M
Antimicrob Agents Chemother; 2008 Oct; 52(10):3637-41. PubMed ID: 18694949
[TBL] [Abstract][Full Text] [Related]
9. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli.
Lionakis MS; Lewis RE; Torres HA; Albert ND; Raad II; Kontoyiannis DP
Diagn Microbiol Infect Dis; 2005 May; 52(1):15-20. PubMed ID: 15878437
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the Sensititre YeastOne and CLSI M38-A2 Microdilution Methods in Determining the Activity of Amphotericin B, Itraconazole, Voriconazole, and Posaconazole against Aspergillus Species.
Wang HC; Hsieh MI; Choi PC; Wu CJ
J Clin Microbiol; 2018 Oct; 56(10):. PubMed ID: 30093391
[TBL] [Abstract][Full Text] [Related]
11. Defining fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations, Monte Carlo simulation analysis, and in vitro-in vivo correlation data for antifungal drug combinations against Aspergillus fumigatus.
Meletiadis J; Pournaras S; Roilides E; Walsh TJ
Antimicrob Agents Chemother; 2010 Feb; 54(2):602-9. PubMed ID: 19995928
[TBL] [Abstract][Full Text] [Related]
12. The development of animal infection models and antifungal efficacy assays against clinical isolates of Trichosporon asahii, T. asteroides and T. inkin.
Mariné M; Bom VL; de Castro PA; Winkelstroter LK; Ramalho LN; Brown NA; Goldman GH
Virulence; 2015; 6(5):476-86. PubMed ID: 25751127
[TBL] [Abstract][Full Text] [Related]
13. Interaction of Amiodarone with Azoles Against Aspergillus Planktonic Cells and Biofilms in vitro.
Duan Z; Tong J; Zheng N; Zeng R; Liu Y; Li M
Mycopathologia; 2022 Dec; 187(5-6):517-526. PubMed ID: 36219382
[TBL] [Abstract][Full Text] [Related]
14. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes.
Sun QN; Fothergill AW; McCarthy DI; Rinaldi MG; Graybill JR
Antimicrob Agents Chemother; 2002 May; 46(5):1581-2. PubMed ID: 11959605
[TBL] [Abstract][Full Text] [Related]
15. Time-Kill Kinetics and In Vitro Antifungal Susceptibility of Non-fumigatus Aspergillus Species Isolated from Patients with Ocular Mycoses.
Öz Y; Özdemir HG; Gökbolat E; Kiraz N; Ilkit M; Seyedmousavi S
Mycopathologia; 2016 Apr; 181(3-4):225-33. PubMed ID: 26612621
[TBL] [Abstract][Full Text] [Related]
16. In vitro interactions of antifungal agents and tacrolimus against Aspergillus biofilms.
Gao L; Sun Y
Antimicrob Agents Chemother; 2015 Nov; 59(11):7097-9. PubMed ID: 26303797
[TBL] [Abstract][Full Text] [Related]
17. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus.
Arikan S; Sancak B; Alp S; Hascelik G; McNicholas P
Med Mycol; 2008 Sep; 46(6):567-73. PubMed ID: 19180726
[TBL] [Abstract][Full Text] [Related]
18. Posaconazole enhances the activity of amphotericin B against Aspergillus hyphae in vitro.
Perkhofer S; Lugger H; Dierich MP; Lass-Flörl C
Antimicrob Agents Chemother; 2007 Feb; 51(2):791-3. PubMed ID: 17116665
[TBL] [Abstract][Full Text] [Related]
19. In Vitro Effects of Farnesol Alone and in Combination with Antifungal Drugs Against Aspergillus Clinical Isolates.
Onder S; Oz Y
Med Mycol J; 2021; 62(1):5-10. PubMed ID: 33642525
[TBL] [Abstract][Full Text] [Related]
20. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
